PE-22-28 research, identity and evidence limits
PE-22-28 is a shortened spadin-derived peptide studied for TREK-1 channel inhibition. Its key experiments concern cells and mouse behavior, not established depression treatment.
Identity and formulation
The 2017 study describes PE-22-28 as a seven-residue product developed from spadin, also called PE 12-28. The parent peptide, the shortened sequence and chemically altered derivatives are not interchangeable.
Terminal changes mattered in the experiments: some modifications changed channel activity. A label saying mini-spadin does not settle the exact sequence or end groups.
What the studies show
The strongest directly matched paper in this source set combines electrophysiology, mouse behavioral assays and neuronal measurements. It supports a pharmacological research hypothesis. Earlier spadin work and later sortilin-derived peptide experiments provide context but cannot be counted as human trials of PE-22-28.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.
Channel assays, mouse behavioral models and cultured neurons Reading scope: PubMed bibliographic record and abstract |
The authors reported stronger TREK-1 inhibition than the parent spadin, altered mouse behavioral measures and longer activity in their experimental system. | Behavioral proxies, exposure conditions and cell markers do not establish antidepressant effectiveness or a safe regimen in people. |
| Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway.
Cell experiments on sortilin-derived peptides and beta-cell survival Reading scope: PubMed bibliographic record and abstract |
PE derivatives, including Mini-Spadin, affected calcium/CREB signaling and survival-related measures under inflammatory stress. | This is pancreatic cell research, not a clinical depression trial or a demonstrated diabetes treatment. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
A lower channel-assay IC50 describes potency in that assay. It cannot be translated directly into a human dose or a claim that symptoms improve faster.
The next useful evidence would include defined formulation and exposure studies, systematic safety assessment and controlled patient outcomes. Repeating a mouse endpoint across related analogues is not an independent demonstration in patients.
Safety context
The studies summarized here do not characterize long-term human psychiatric, neurological or interaction risks. Absence of those data should remain visible beside benefit claims.
Study exposure and units
Keep nanomolar assay potency, animal exposure and observed duration in their original experimental units. A reported duration of behavioral activity is not a human dosing interval.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Require the full seven-residue sequence and terminal chemistry, and determine whether the material is parent PE-22-28 or a modified derivative. A report for spadin cannot establish the identity of the shortened product.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does TREK-1 inhibition prove an antidepressant effect in people?
No. It identifies a possible biological target. Clinical benefit requires patient outcomes, a suitable comparator and a characterized exposure; none is supplied by a channel experiment.
Can a paper about spadin be used as a PE-22-28 trial?
Only as clearly labeled related-molecule context unless the methods actually test the shortened peptide. The 2015 source concerns SID1900 and spadin, so it is not a direct PE-22-28 efficacy trial.
Sources
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. (PubMed bibliographic record and abstract)
- Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway. (PubMed bibliographic record and abstract)